Brand name: Olanzapine (AN)
Olanzapine (AN) is a medicine containing the active ingredient(s) olanzapine. On this page you will find out more about Olanzapine (AN), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: olanzapine
Over 65 years of age?
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Olanzapine (AN) 10 mg film-coated tablet, 28
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
For the treatment of schizophrenia and related psychoses. ,Alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. ,For preventing recurrence of manic, mixed or depressive episodes in Bipolar I Disorder.
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance | White, round, biconvex film coated tablets |
| Dosage Form | Tablet, film coated |
| Route of administration | Oral |
| Medicine schedule |
10: Prescription Only Medicine, or Prescription Animal Remedy
14: Prescription Only Medicine, or Prescription Animal Remedy
20: Prescription Only Medicine, or Prescription Animal Remedy
21: Prescription Only Medicine, or Prescription Animal Remedy
28: Prescription Only Medicine, or Prescription Animal Remedy
30: Prescription Only Medicine, or Prescription Animal Remedy
40: Prescription Only Medicine, or Prescription Animal Remedy
50: Prescription Only Medicine, or Prescription Animal Remedy
60: Prescription Only Medicine, or Prescription Animal Remedy
7: Prescription Only Medicine, or Prescription Animal Remedy
|
There is one type of pack available.
Pack type 1
| Type | Blister Pack |
|---|---|
| Storage temperature | Store below 30 degrees Celsius |
| Storage conditions | Store in Original Container |
| Life time | 3 Years |
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 October 2017
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 58 results
Olanzapine AN Tablets - myDr.com.au
Olanzapine AN Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Olanzapine GH Tablets - myDr.com.au
Olanzapine GH Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Olanzapine-PS Tablets - myDr.com.au
Olanzapine-PS Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Olanzapine Generichealth Tablets - myDr.com.au
Olanzapine Generichealth Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
APO-Olanzapine Tablets - myDr.com.au
APO-Olanzapine Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Pharmacy Choice Olanzapine Tablets - myDr.com.au
Pharmacy Choice Olanzapine Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Olanzapine AN ODT Orally disintegrating tablets - myDr.com.au
Olanzapine AN ODT Orally disintegrating tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
PS Olanzapine ODT (orally disintegrating tablets) - myDr.com.au
PS Olanzapine ODT (orally disintegrating tablets) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Stada Olanzapine ODT Orally disintegrating tablets - myDr.com.au
Stada Olanzapine ODT Orally disintegrating tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Olanzapine RBX ODT Orally disintegrating tablets - myDr.com.au
Olanzapine RBX ODT Orally disintegrating tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 46 results
Olanzapine versus other atypical antipsychotics for schizophrenia | Cochrane
This review examined the effects of olanzapine compared to other second generation antipsychotic drugs for schizophrenia. We identified 50 relevant studies with 9476 participants, comparing olanzapine with amisulpride, aripiprazole, clozapine, quetiapine, risperidone and ziprasidone. Comparisons of olanzapine with the second generation antipsychotic drugs sertindole or zotepine are currently not available. Olanzapine was somewhat more efficacious than aripiprazole, quetiapine, risperidone and ziprasidone, whereas there was no efficacy difference compared to amisulpride and clozapine. The main disadvantage of olanzapine was its higher weight gain and associated metabolic problems compared to all other second generation antipsychotic drugs, except for clozapine.
Read more on Cochrane (Australasian Centre) website
Olanzapine for schizophrenia | Cochrane
Since the early 1950s the mainstay of treatment for schizophrenia has been the typical antipsychotics such as chlorpromazine and haloperidol. Although they are effective in controlling voices and delusions for many people with schizophrenia, they have a smaller effect on symptoms such as apathy and social withdrawal. They also have disabling adverse effects such as tremor, stiffness and slowing of movement. The newer drugs, such as olanzapine, are reputed to have fewer adverse motor effects and are as effective, if not more so, than the older drugs. This review examines the randomised controlled trials of olanzapine compared with placebo, typical and atypical antipsychotic drugs.
Read more on Cochrane (Australasian Centre) website
Olanzapine in long-term treatment for bipolar disorder | Cochrane
Bipolar affective disorder is a severe and common mental illness, characterised by periods of mania, depression and "mixed episodes" (or "dysphoric mania": a mixture of manic and depressed symptoms). Antipsychotic drugs are often used to treat acute manic episodes and one commonly used antipsychotic drug that has recently been approved for use in mania in USA and Europe is olanzapine. This review considered the efficacy, acceptability and adverse effects of olanzapine in long-term treatment of bipolar disorder in comparison with placebo or other active drug comparisons. Five trials (1165 participants) met the inclusion criteria and are included in the review. Based on a limited amount of information, olanzapine may prevent further mood episodes (especially manic relapse) in patients who responded to olanzapine during an index manic or mixed episode and who have not previously had a satisfactory response to lithium or valproate. The olanzapine group had significantly fewer patients suffering from insomnia than the placebo group, but a significantly larger number of people suffering from weight gain. When compared with lithium, olanzapine caused more weight gain and depressive symptoms but fewer insomnia and nausea symptoms and a lower rate of manic worsening. However, considering the lack of clear findings of this review, conclusions on efficacy and acceptability of olanzapine compared to placebo, lithium or valproate cannot be made with any degree of confidence
Read more on Cochrane (Australasian Centre) website
Olanzapine compared to placebo or other medicine as treatment for mania | Cochrane
High withdrawal rates from the trials limit the confidence that can be placed on the results. Olanzapine was superior to placebo in reduction of manic symptoms both as monotherapy and combined with mood stabilizers, though caused weight gain. Olanzapine was more efficacious than divalproex and caused less nausea but more weight gain, somnolence and movement disorders. Olanzapine was comparable to haloperidol in efficacy, caused less movement disorders but greater weight gain.
Read more on Cochrane (Australasian Centre) website
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses | Cochrane
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses
Read more on Cochrane (Australasian Centre) website
Risperidone versus olanzapine for schizophrenia | Cochrane
Read more on Cochrane (Australasian Centre) website
Clozapine versus other atypical antipsychotics for schizophrenia | Cochrane
This review compared the clinical effects of clozapine with the other atypical antipsychotics. Twenty-seven studies fulfilled the review's criteria and provided data to compare clozapine with antipsychotics such as olanzapine, quetiapine, risperidone, ziprasidone and zotepine. Clozapine was somewhat more efficacious than zotepine. Also, inefficacy of treatment led more frequently to leaving the studies early in the risperidone group suggesting a certain higher efficacy of clozapine. The principal drawback of clozapine were its adverse effects which lead to significantly higher numbers of participants leaving the studies early compared to olanzapine and risperidone. Clozapine was associated with more sedation and hypersalivation than olanzapine, quetiapine and risperidone and with more seizures than olanzapine and risperidone. There was a higher incidence of white blood cell decrease in clozapine groups than olanzapine and more weight gain than in risperidone groups. On the other hand clozapine produced fewer movement disorder than risperidone and less prolactin increase than olanzapine, quetiapine and zotepine.
Read more on Cochrane (Australasian Centre) website
Second-generation antipsychotic drugs for obsessive compulsive disorder | Cochrane
This review found some trials comparing the effects of adding second-generation antipsychotic drugs or placebo to antidepressants in obsessive compulsive disorder. There were only 11 trials on three second-generation antipsychotic drugs (olanzapine, quetiapine and risperidone). While not much can be said about olanzapine, quetiapine and risperidone showed some efficacy benefit, but also adverse effects.
Read more on Cochrane (Australasian Centre) website
Amisulpride versus other atypical antipsychotics for schizophrenia | Cochrane
This review compared the effects of amisulpride with those of other so called second generation (atypical) antipsychotic drugs. For half of the possible comparisons not a single relevant study could be identified. Based on very limited data there was no difference in efficacy comparing amisulpride with olanzapine and risperidone, but a certain advantage compared with ziprasidone. Amisulpride was associated with less weight gain than risperidone and olanzapine.
Read more on Cochrane (Australasian Centre) website
Risperidone versus other atypical antipsychotics for schizophrenia | Cochrane
This review examines the effects of risperidone compared to other second-generation antipsychotic (SGA) drugs for schizophrenia. We identified 45 relevant studies with 7760 participants comparing risperidone with amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, sertindole and ziprasidone. Comparisons of risperidone with zotepine are currently not available. Risperidone was somewhat more successful than quetiapine and ziprasidone, but somewhat less successful than clozapine and olanzapine. The main disadvantage of risperidone were more frequent movement disorders and more prolactin increase compared to most other SGA drugs.
Read more on Cochrane (Australasian Centre) website
